Table 1 Patient demographics and clinical characteristics of The Cancer Genome Atlas (TCGA) clear cell renal cell carcinoma (ccRCC) cohort (n = 463 with available RNA-Seq data), as well as our cohorts (n = 52 with available microarray data; n = 108 with available RT-PCR data) and a sunitinib-treated cohort published by Beuselinck et al. [17]a (n = 53)
ccRCC TCGA (n = 463) | ccRCC cohort 1 (n = 52) | Sunitinib treated cohorta (n = 53) | Extended ccRCC cohort 2b (n = 108) | ||||||
|---|---|---|---|---|---|---|---|---|---|
n, value | % | n, value | % | n, value | % | n, value | % | ||
Sex | Male | 297 | 64.15% | 35 | 67.3% | 37 | 69.81% | 63 | 58.33% |
Female | 166 | 35.85% | 17 | 32.69% | 16 | 30.19% | 45 | 41.67% | |
Age (year) | Median (range) | 61 (26–90) | 64 (37–90) | 58 (44–80) | 65 (34–90) | ||||
T | T1 | 226 | 48.81% | 17 | 32.69% | NA | NA | 51 | 47.22% |
T2 | 59 | 12.74% | 4 | 7.69% | NA | NA | 10 | 9.26% | |
T3 | 168 | 36.29% | 31 | 59.62% | NA | NA | 47 | 43.52% | |
T4 | 10 | 2.16% | 0 | 0.00% | NA | NA | 0 | 0.00% | |
N | N0 | 215 | 46.44% | 46 | 88.46% | NA | NA | 97 | 89.81% |
N1 | 15 | 3.24% | 4 | 7.69% | NA | NA | 8 | 7.41% | |
N2 | 0 | 0.00% | 2 | 3.85% | NA | NA | 3 | 2.78% | |
NX | 233 | 50.32% | 0 | 0.00% | NA | NA | 0 | 0.00% | |
M | M0 | 374 | 80.78% | 41 | 78.85% | NA | NA | 92 | 85.19% |
M1 | 76 | 16.41% | 10 | 19.23% | NA | NA | 15 | 13.89% | |
MX | 13 | 2.81% | 1 | 1.92% | NA | NA | 1 | 0.93% | |
G | G1 | 7 | 1.51% | 9 | 17.31% | NA | NA | 24 | 22.22% |
G2 | 200 | 43.20% | 30 | 57.69% | NA | NA | 60 | 55.56% | |
G2–G3 | 0 | 0.00% | 1 | 1.92% | NA | NA | 2 | 1.85% | |
G3 | 183 | 39.52% | 11 | 21.15% | NA | NA | 20 | 18.52% | |
G4 | 72 | 15.55% | 1 | 1.92% | NA | NA | 1 | 0.93% | |
GX | 1 | 0.22% | 0 | 0.00% | NA | NA | 0 | 0.00% | |
NA | 0 | 0.00% | 0 | 0.00% | NA | NA | 1 | 0.93% | |
Necrosis | Present | 218 | 47.08% | 10 | 19.23% | NA | NA | 17 | 15.74% |
Absent | 245 | 52.92% | 42 | 80.77% | NA | NA | 91 | 84.26% | |
Follow-up time (years) | Median (range) | 3.1 (0.0–10.0) | 3.0 (0.0–10.0) | 1.0 (0.1–4.9) | 3.4 (0.0–11.1) | ||||
Overall survival | Deceased | 152 | 32.83% | 17 | 32.69% | NA | NA | 29 | 26.85% |
Alive | 311 | 67.17% | 35 | 67.31% | NA | NA | 79 | 73.15% | |
Cancer-specific survival | Cancer-related death | 104 | 22.46% | 15 | 28.85% | NA | NA | 21 | 19.44% |
Alive/non-cancer-related death | 359 | 77.54% | 37 | 71.15% | NA | NA | 87 | 80.56% | |
Progression free survival under sunitinib therapy | Yes | – | – | – | – | 14 | 26.4% | – | – |
No | – | – | – | – | 39 | 73.6% | – | – | |